New vaccine aims to fight rare abdominal cancer
NCT ID NCT07341360
First seen Jan 16, 2026 · Last updated May 23, 2026 · Updated 23 times
Summary
This early-phase trial tests a cancer vaccine called Pseudovax, given with an immunotherapy drug (tislelizumab), in 10 adults with a rare abdominal cancer called pseudomyxoma peritonei that has a specific gene mutation (GNAS). The goal is to see if the combination is safe and can boost the immune system to fight the cancer. Participants receive treatment for up to two years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSEUDOMYXOMA PERITONEI are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Oslo University Hospital HF, Radium
RECRUITINGOslo, Oslo, 0379, Norway
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.